Showing 4391-4400 of 8791 results for "".
- DataDerm in Action: AAD Launches Project to Improve Outcomes for GPP Patientshttps://practicaldermatology.com/news/aad-launches-project-to-improve-outcomes-for-gpp-patients/2461804/The American Academy of Dermatology is launching a new project to develop educational resources to improve the evaluation, diagnosis, and treatment of patients with generalized pustular psoriasis (GPP). The AAD is working with Boehringer Ingelheim and using OM1’s data aggregation
- Paradigm Shift: Can Harnessing the Power of Healthy Cells Prevent Skin Cancer?https://practicaldermatology.com/news/paradigm-switch-can-harnessing-the-power-of-healthy-cells-prevent-skin-cancer/2461803/Do simple wounds or surgery increase skin cancer risks by expanding mutated cells? No, according to a new study by researchers at Yale and the Karolinska Institute in Sweden. Rather than promoting mutant cell growth, injury promotes healthy-cell expansion which keeps mutated cell growth
- Osteopontin Potently Stimulates Hair Follicle Stem Cells for Robust Hair Growthhttps://practicaldermatology.com/news/osteopontin-potently-stimulates-hair-follicle-stem-cells-for-robust-hair-growth/2461802/Do hairy moles hold the secret to understanding hair growth? Maybe, according to research published in the June 21, 2023 issue of Nature. Using a mouse model, researchers tracked the activity of ha
- Proof of Concept: Oral Orismilast Reduces Pain, Improves Q of L in HShttps://practicaldermatology.com/news/proof-of-concept-oral-orismilast-reduces-pain-improves-q-of-l-in-hs/2461799/Oral orismilast is showing promise in adult with hidradenitis suppurativa (HS), according to positive topline results from the OSIRIS investigator-initiated proof-of-concept study. UNION therapeutics’ Orismilast is a high potency, next-generation PDE4
- Almirall Launches New Series Highlighting the Impact of Psoriasis on Wellbeinghttps://practicaldermatology.com/news/almirall-launches-new-series-highlighting-the-impact-of-psoriasis-on-wellbeing/2461795/Almirall has launched Nina, a three-episode series about the life of a fashion designer with psoriasis to illustrate a journey from darkness to light. Nina narrates the story of an introverted designer portrayed by Spanish actress Alba Ribas (Cable Girls, Netflix). One da
- Health Canada Greenlights Sun Pharma’s Winlevi for Acnehttps://practicaldermatology.com/news/health-canada-greenlights-sun-pharmas-winlevi-for-acne/2461792/Health Canada has given its nod to Sun Pharma’s Winlevi (clascoterone cream 1%). Winlevi an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. It will be available in Canada this Fall. "
- Dr. Michele L. Ramien Takes the Helm as President of the Canadian Dermatology Associationhttps://practicaldermatology.com/news/dr-michele-l-ramien-takes-the-helm-as-president-of-the-canadian-dermatology-association/2461789/Dr. Michele L. Ramien is the new president of The Canadian Dermatology Association (CDA). “I want to increase engagement amongst our members by re-imagining how our community interacts so that - united - we are ready to accomplish all the work we need to do,” says Dr.
- FDA Nod for Avita Medical’s RECELL for Skin Repigmentation in Vitiligo Patientshttps://practicaldermatology.com/news/fda-nod-for-avita-medicals-recell-for-skin-repigmentation-in-vitiligo-patients/2461787/The U.S. Food and Drug Administration (FDA) has approved AVITA Medical, Inc.’s application for premarket approval (PMA) of its RECELL System for the treatment of vitiligo. RECELL for repigmentation of stable depigmented vitiligo lesions is the first FDA-approved therapeutic d
- Vial, Nielsen BioSciences Partner in Phase III Clinical Trial of Candin for Common Wartshttps://practicaldermatology.com/news/vial-nielsen-biosciences-partner-in-phase-iii-clinical-trial-of-candin-for-common-warts/2461783/Vial is partnering with
- Merz Aesthetics News: Xeomin Scores in Phase 3 Studies of Upper Facial Lineshttps://practicaldermatology.com/news/merz-aesthetics-news-xeomin-performs-well-in-phase-3-studies-of-upper-facial-lines/2461781/Two pivotal phase 3 clinical studies demonstrated the efficacy and safety of Xeomin (incobotulinumtoxinA) in the simultaneous treatment of horizontal forehead lines, glabellar frown lines, and lateral canthal lines, according to Merz Aesthetics. Merz Aesthetics will submit these data as